Technical Analysis for RARE - Ultragenyx Pharmaceutical Inc.
|Grade||Last Price||% Change||Price Change|
RARE closed up 4.98 percent on Tuesday, January 15, 2019, on approximately normal volume. It was able to find support at its 50 day moving average. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
|See historical RARE trend table...|
|Date||Alert Name||Type||% Chg|
|Jan 15||50 DMA Support||Bullish||2.87%|
|Jan 15||MACD Bullish Centerline Cross||Bullish||2.87%|
|Jan 15||Upper Bollinger Band Walk||Strength||2.87%|
|Jan 15||Multiple of Ten Bullish||Other||2.87%|
|Jan 15||Wide Bands||Range Expansion||2.87%|
|Jan 15||Above Upper BB||Strength||2.87%|
|Jan 15||Overbought Stochastic||Strength||2.87%|
|Jan 15||Upper Bollinger Band Touch||Strength||2.87%|
|Jan 14||50 DMA Support||Bullish||8.00%|
|Jan 14||Upper Bollinger Band Walk||Strength||8.00%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Ultragenyx Pharmaceutical Inc., a development-stage biotechnology company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare diseases in the United States. It develops various biologics product candidates, including KRN23, a human monoclonal antibody to bind and reduce the biological activity of fibroblast growth factor to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia; recombinant human beta-glucuronidase, an intravenous enzyme replacement therapy for the treatment of mucopolysaccharidosis 7; and recombinant human protective protein cathepsin-A, an enzyme replacement therapy for galactosialidosis. The company is also developing a range of small-molecule product candidates comprising triheptanoin, a substrate replacement therapy for patients with fatty acid oxidation disorders, as well as for patients with glucose transporter type-1 deficiency syndrome; and oral formulation of sialic acid to treat hereditary inclusion body myopathy. It has license agreements with AAI Pharma Services Corp. and HIBM Research Group; and a collaboration and license agreement with Nobelpharma Co., Ltd. The company was founded in 2010 and is headquartered in Novato, California.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more RARE news...
|52 Week High||90.98|
|52 Week Low||37.44|
|200-Day Moving Average||65.8035|
|50-Day Moving Average||48.4682|
|20-Day Moving Average||44.0415|
|10-Day Moving Average||45.971|
|Average True Range||2.9116|
|Chandelier Exit (Long, 3 ATRs )||42.8952|
|Chandelier Exit (Short, 3 ATRs )||46.1748|
|Upper Bollinger Band||50.803|
|Lower Bollinger Band||37.28|
|Percent B (%b)||1.03|
|MACD Signal Line||-1.2702|
|Market Cap||2.18 Billion|
|Num Shares||42.6 Million|
|Price-to-Earnings (P/E) Ratio||-7.60|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||56.06|
|Resistance 3 (R3)||55.66||53.65||55.25|
|Resistance 2 (R2)||53.65||52.41||53.85||54.98|
|Resistance 1 (R1)||52.42||51.64||53.04||52.82||54.71|
|Support 1 (S1)||49.18||49.17||49.80||49.58||47.69|
|Support 2 (S2)||47.17||48.40||47.37||47.42|
|Support 3 (S3)||45.94||47.17||47.15|
|Support 4 (S4)||46.34|